Progyny Inc (PGNY) - Net Assets
Based on the latest financial reports, Progyny Inc (PGNY) has net assets worth $516.04 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($742.43 Million) and total liabilities ($226.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PGNY cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $516.04 Million |
| % of Total Assets | 69.51% |
| Annual Growth Rate | 62.35% |
| 5-Year Change | 104.92% |
| 10-Year Change | N/A |
| Growth Volatility | 298.5 |
Progyny Inc - Net Assets Trend (2017–2025)
This chart illustrates how Progyny Inc's net assets have evolved over time, based on quarterly financial data. Also explore Progyny Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Progyny Inc (2017–2025)
The table below shows the annual net assets of Progyny Inc from 2017 to 2025. For live valuation and market cap data, see Progyny Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $516.04 Million | +22.27% |
| 2024-12-31 | $422.06 Million | -23.74% |
| 2023-12-31 | $553.43 Million | +46.81% |
| 2022-12-31 | $376.97 Million | +49.70% |
| 2021-12-31 | $251.82 Million | +50.84% |
| 2020-12-31 | $166.95 Million | +46.10% |
| 2019-12-31 | $114.27 Million | +927.43% |
| 2018-12-31 | $11.12 Million | +4.04% |
| 2017-12-31 | $10.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Progyny Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 30738300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $202.83 Million | 39.30% |
| Common Stock | $9.00K | 0.00% |
| Other Comprehensive Income | $498.00K | 0.10% |
| Other Components | $312.71 Million | 60.60% |
| Total Equity | $516.04 Million | 100.00% |
Progyny Inc Competitors by Market Cap
The table below lists competitors of Progyny Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fair Oaks Income Limited
LSE:FAIR
|
$1.50 Billion |
|
Faes Farma SA
MC:FAE
|
$1.50 Billion |
|
Tessenderlo
BR:TESB
|
$1.50 Billion |
|
Concentrix Corporation
NASDAQ:CNXC
|
$1.50 Billion |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
$1.49 Billion |
|
Huabao Flavours & Fragrances Co Ltd Class A
SHE:300741
|
$1.49 Billion |
|
Jiangsu Sanfangxiang Industry Co Ltd
SHG:600370
|
$1.49 Billion |
|
Global Blue Group Holding Ltd
NYSE:GB
|
$1.49 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Progyny Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 422,062,000 to 516,044,000, a change of 93,982,000 (22.3%).
- Net income of 58,520,000 contributed positively to equity growth.
- Share repurchases of 81,657,000 reduced equity.
- Other comprehensive income increased equity by 459,000.
- Other factors increased equity by 116,660,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $58.52 Million | +11.34% |
| Share Repurchases | $81.66 Million | -15.82% |
| Other Comprehensive Income | $459.00K | +0.09% |
| Other Changes | $116.66 Million | +22.61% |
| Total Change | $- | 22.27% |
Book Value vs Market Value Analysis
This analysis compares Progyny Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.90x to 3.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $1.88 | $18.60 | x |
| 2018-12-31 | $0.14 | $18.60 | x |
| 2019-12-31 | $1.37 | $18.60 | x |
| 2020-12-31 | $1.69 | $18.60 | x |
| 2021-12-31 | $2.51 | $18.60 | x |
| 2022-12-31 | $3.77 | $18.60 | x |
| 2023-12-31 | $5.50 | $18.60 | x |
| 2024-12-31 | $4.42 | $18.60 | x |
| 2025-12-31 | $5.77 | $18.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Progyny Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.34%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.54%
- • Asset Turnover: 1.74x
- • Equity Multiplier: 1.44x
- Recent ROE (11.34%) is above the historical average (-2.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -116.48% | -25.63% | 1.39x | 3.27x | $-13.52 Million |
| 2018 | 5.94% | 0.63% | 2.55x | 3.72x | $-451.20K |
| 2019 | -7.50% | -3.73% | 1.53x | 1.32x | $-20.00 Million |
| 2020 | 27.83% | 13.47% | 1.36x | 1.52x | $29.76 Million |
| 2021 | 26.12% | 13.14% | 1.40x | 1.42x | $40.59 Million |
| 2022 | 8.05% | 3.86% | 1.45x | 1.44x | $-7.34 Million |
| 2023 | 11.21% | 5.70% | 1.44x | 1.37x | $6.69 Million |
| 2024 | 12.87% | 4.66% | 1.92x | 1.44x | $12.13 Million |
| 2025 | 11.34% | 4.54% | 1.74x | 1.44x | $6.92 Million |
Industry Comparison
This section compares Progyny Inc's net assets metrics with peer companies in the Healthcare Plans industry.
Industry Context
- Industry: Healthcare Plans
- Average net assets among peers: $8,617,362,400
- Average return on equity (ROE) among peers: -51.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Progyny Inc (PGNY) | $516.04 Million | -116.48% | 0.44x | $1.49 Billion |
| Alignment Healthcare LLC (ALHC) | $30.61 Million | -74.89% | 10.06x | $3.77 Billion |
| Cigna Corp (CI) | $4.52 Billion | 13.99% | 19.13x | $74.53 Billion |
| Clover Health Investments Corp (CLOV) | $308.70 Million | -27.71% | 0.75x | $1.00 Billion |
| Centene Corp (CNC) | $64.09 Million | 20.12% | 1.05x | $19.48 Billion |
| CVS Health Corp (CVS) | $37.96 Billion | 12.23% | 0.95x | $101.04 Billion |
| Elevance Health Inc (ELV) | $24.58 Billion | 12.59% | 1.11x | $63.54 Billion |
| Humana Inc (HUM) | $17.37 Billion | 7.04% | 0.15x | $22.79 Billion |
| Molina Healthcare Inc (MOH) | $64.76 Million | 46.52% | 1.31x | $6.97 Billion |
| Marpai Inc (MRAI) | $6.13 Million | -431.51% | 7.14x | $6.21 Million |
| NeueHealth Inc (NEUE) | $1.27 Billion | -93.04% | 1.83x | $60.94 Million |
About Progyny Inc
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers … Read more